| 1. |
- Meier Valdes, E., et al.
(författare)
-
Investigating the visible phase-curve variability of 55 Cnc e
- 2023
-
Ingår i: Astronomy and Astrophysics. - 0004-6361 .- 1432-0746. ; 677
-
Tidskriftsartikel (refereegranskat)abstract
- Context. 55 Cnc e is an ultra-short period super-Earth transiting a Sun-like star. Previous observations in the optical range detected a time-variable flux modulation that is phased with the planetary orbital period, whose amplitude is too large to be explained by reflected light and thermal emission alone. Aims. The goal of the study is to investigate the origin of the variability and timescale of the phase-curve modulation in 55 Cnc e. To this end, we used the CHaracterising ExOPlanet Satellite (CHEOPS), whose exquisite photometric precision provides an opportunity to characterise minute changes in the phase curve from one orbit to the next. Methods. CHEOPS observed 29 individual visits of 55 Cnc e between March 2020 and February 2022. Based on these observations, we investigated the different processes that could be at the origin of the observed modulation. In particular, we built a toy model to assess whether a circumstellar torus of dust driven by radiation pressure and gravity might match the observed flux variability timescale. Results. We find that the phase-curve amplitude and peak offset of 55 Cnc e do vary between visits. The sublimation timescales of selected dust species reveal that silicates expected in an Earth-like mantle would not survive long enough to explain the observed phase-curve modulation. We find that silicon carbide, quartz, and graphite are plausible candidates for the circumstellar torus composition because their sublimation timescales are long. Conclusions. The extensive CHEOPS observations confirm that the phase-curve amplitude and offset vary in time. We find that dust could provide the grey opacity source required to match the observations. However, the data at hand do not provide evidence that circumstellar material with a variable grain mass per unit area causes the observed variability. Future observations with the James Webb Space Telescope (JWST) promise exciting insights into this iconic super-Earth.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Quanz, S. P., et al.
(författare)
-
Large Interferometer For Exoplanets (LIFE) I. Improved exoplanet detection yield estimates for a large mid-infrared space-interferometer mission
- 2022
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 664
-
Tidskriftsartikel (refereegranskat)abstract
- Context. One of the long-term goals of exoplanet science is the atmospheric characterization of dozens of small exoplanets in order to understand their diversity and search for habitable worlds and potential biosignatures. Achieving this goal requires a space mission of sufficient scale that can spatially separate the signals from exoplanets and their host stars and thus directly scrutinize the exoplanets and their atmospheres.Aims. We seek to quantify the exoplanet detection performance of a space-based mid-infrared (MIR) nulling interferometer that measures the thermal emission of exoplanets. We study the impact of various parameters and compare the performance with that of large single-aperture mission concepts that detect exoplanets in reflected light.Methods. We have developed an instrument simulator that considers all major astrophysical noise sources and coupled it with Monte Carlo simulations of a synthetic exoplanet population around main-sequence stars within 20 pc of the Sun. This allows us to quantify the number (and types) of exoplanets that our mission concept could detect. Considering single visits only, we discuss two different scenarios for distributing 2.5 yr of an initial search phase among the stellar targets. Different apertures sizes and wavelength ranges are investigated.Results. An interferometer consisting of four 2 m apertures working in the 4–18.5 μ.m wavelength range with a total instrument throughput of 5% could detect up to ≈550 exoplanets with radii between 0.5 and 6 R⊕ with an integrated S/N ≥ 7. At least ≈160 of the detected exoplanets have radii ≤1.5 R⊕. Depending on the observing scenario, ≈25–45 rocky exoplanets (objects with radii between 0.5 and 1.5 R⊕) orbiting within the empirical habitable zone (eHZ) of their host stars are among the detections. With four 3.5 m apertures, the total number of detections can increase to up to ≈770, including ≈60–80 rocky eHZ planets. With four times 1 m apertures, the maximum detection yield is ≈315 exoplanets, including ≤20 rocky eHZ planets. The vast majority of small, temperate exoplanets are detected around M dwarfs. The impact of changing the wavelength range to 3–20 μm or 6–17 μm on the detection yield is negligible.Conclusions. A large space-based MIR nulling interferometer will be able to directly detect hundreds of small, nearby exoplanets, tens of which would be habitable world candidates. This shows that such a mission can compete with large single-aperture reflected light missions. Further increasing the number of habitable world candidates, in particular around solar-type stars, appears possible via the implementation of a multi-visit strategy during the search phase. The high median S/N of most of the detected planets will allow for first estimates of their radii and effective temperatures and will help prioritize the targets for a second mission phase to obtain high-S/N thermal emission spectra, leveraging the superior diagnostic power of the MIR regime compared to shorter wavelengths.
|
|
| 5. |
- Chong, K. Y., et al.
(författare)
-
A core outcome set for future research in ectopic pregnancy: an international consensus development study
- 2023
-
Ingår i: Fertility and Sterility. - : Elsevier BV. - 0015-0282. ; 119:5, s. 804-812
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To address methodological deficiencies in published randomized controlled trials and systematic reviews, this study has developed a core outcome set to guide future research in ectopic pregnancy (EP).Design: To identify potential outcomes, we performed a comprehensive literature review and interviews with individuals with lived experience in EP. Potential core outcomes were then entered into a 3-round Delphi survey. A total of 154 participants from 6 continents, comprising health care professionals, researchers, and individuals with lived experience in EP, completed all 3 rounds of the Delphi survey. Outcomes were prioritized at 3 consensus development meetings, and recommendations were developed on how to report these outcomes where possible.Setting: Not applicable.Patient(s): Health care professionals, researchers, and individuals with lived experience in EP.Intervention(s): Not applicable.Main Outcome Measure(s): Consensus for inclusion in core outcome set.Result(s): Six outcomes reached full consensus, including treatment success, resolution time, the number of additional interventions, adverse events, mortality and severe morbidity, and treatment satisfaction.Conclusion(s): The core outcome set with 6 outcomes for EP will help standardize reporting of clinical trials, facilitate implementation of findings into clinical practice, and enhance patient-centered care. (Fertil Sterile 2023;119:804-12. (c) 2023 by American Society for Reproductive Medicine.) El resumen esta disponible en Espanol al final del articulo.
|
|
| 6. |
- Chong, K. Y., et al.
(författare)
-
A protocol for developing a core outcome set for ectopic pregnancy
- 2021
-
Ingår i: Trials. - : Springer Science and Business Media LLC. - 1745-6215. ; 22:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Randomised controlled trials (RCTs) evaluating ectopic pregnancy have reported many different outcomes, which are themselves often defined and measured in distinct ways. This level of variation results in an inability to compare results of individual RCTs. The development of a core outcome set to ensure outcomes important to key stakeholders are collected consistently will guide future research in ectopic pregnancy. Study aim: To develop and implement a core outcome set to guide future research in ectopic pregnancy. Methods and analysis: We have established an international steering group of key stakeholders, including healthcare professionals, researchers, and individuals with lived experience of ectopic pregnancy. We will identify potential outcomes from ectopic pregnancy from a comprehensive literature review of published randomised controlled trials. We will then utilise a modified Delphi method to prioritise outcomes. Subsequently, key stakeholders will be invited to score potential core outcomes on a nine-point Likert scale, ranging from 1 (not important) to 9 (critical). Repeated reflection and rescoring should promote whole and individual stakeholder group convergence towards consensus 'core' outcomes. We will also establish standardised definitions and recommend high-quality measurements for individual core outcomes.
|
|
| 7. |
- Mirza, M. R., et al.
(författare)
-
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- 2016
-
Ingår i: New England Journal of Medicine. - : MASSACHUSETTS MEDICAL SOC. - 0028-4793 .- 1533-4406. ; 375:22, s. 2154-2164
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P amp;lt; 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.)
|
|
| 8. |
- Powell, Diana, et al.
(författare)
-
Sulfur dioxide in the mid-infrared transmission spectrum of WASP-39b
- 2024
-
Ingår i: Nature. - 0028-0836 .- 1476-4687. ; 626:8001, s. 979-983
-
Tidskriftsartikel (refereegranskat)abstract
- The recent inference of sulfur dioxide (SO2) in the atmosphere of the hot (approximately 1,100 K), Saturn-mass exoplanet WASP-39b from near-infrared JWST observations1–3 suggests that photochemistry is a key process in high-temperature exoplanet atmospheres4. This is because of the low (<1 ppb) abundance of SO2 under thermochemical equilibrium compared with that produced from the photochemistry of H2O and H2S (1–10 ppm)4–9. However, the SO2 inference was made from a single, small molecular feature in the transmission spectrum of WASP-39b at 4.05 μm and, therefore, the detection of other SO2 absorption bands at different wavelengths is needed to better constrain the SO2 abundance. Here we report the detection of SO2 spectral features at 7.7 and 8.5 μm in the 5–12-μm transmission spectrum of WASP-39b measured by the JWST Mid-Infrared Instrument (MIRI) Low Resolution Spectrometer (LRS)10. Our observations suggest an abundance of SO2 of 0.5–25 ppm (1σ range), consistent with previous findings4. As well as SO2, we find broad water-vapour absorption features, as well as an unexplained decrease in the transit depth at wavelengths longer than 10 μm. Fitting the spectrum with a grid of atmospheric forward models, we derive an atmospheric heavy-element content (metallicity) for WASP-39b of approximately 7.1–8.0 times solar and demonstrate that photochemistry shapes the spectra of WASP-39b across a broad wavelength range.
|
|
| 9. |
- Oza, Amit M., et al.
(författare)
-
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial
- 2018
-
Ingår i: The Lancet Oncology. - 1470-2045. ; 19:8, s. 1117-1125
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Quality of life (QOL) has become an important complementary endpoint in cancer clinical studies alongside more traditional assessments (eg, tumour response, progression-free survival, overall survival). Niraparib maintenance treatment has been shown to significantly improve progression-free survival in patients with recurrent ovarian cancer. We aimed to assess whether the benefits of extending progression-free survival are offset by treatment-associated toxic effects that affect QOL. Methods: The ENGOT-OV16/NOVA trial was a multicentre, double-blind, phase 3, randomised controlled trial done in 107 study sites in the USA, Canada, Europe, and Israel. Patients with recurrent ovarian cancer who were in response to their last platinum-based chemotherapy were randomly assigned (2:1) to receive either niraparib (300 mg once daily) as a maintenance treatment or placebo. Randomisation was stratified based on time to progression after the penultimate platinum-based regimen, previous use of bevacizumab, and best response (complete or partial) to the last platinum-based regimen with permuted-block randomisation (six in each block) using an interactive web response system. The trial enrolled two independent cohorts on the basis of germline BRCA (gBRCA) mutation status (determined by BRACAnalysis Testing, Myriad Genetics, Salt Lake City, UT, USA). The primary endpoint of the trial was progression-free survival, and has already been reported. In this study, we assessed patient-reported outcomes (PROs) in the intention-to-treat population using the Functional Assessment of Cancer Therapy–Ovarian Symptoms Index (FOSI) and European QOL five-dimension five-level questionnaire (EQ-5D-5L). We collected PROs from trial entry every 8 weeks for the first 14 cycles and every 12 weeks thereafter. If a patient discontinued, we collected PROs at discontinuation and during a postprogression visit 8 weeks (plus or minus 2 weeks) later. We assessed the effect of haematological toxic effects on QOL with disutility analyses of the most common grade 3–4 adverse events (thrombocytopenia, anaemia, and neutropenia) using a mixed model with histology, region, previous treatment, age, planned treatment, and baseline score as covariates. This study is registered with ClinicalTrials.gov, number NCT01847274. Findings: Between Aug 28, 2013, and June 1, 2015, 553 patients were enrolled and randomly assigned to receive niraparib (n=138 in the gBRCAmut cohort, n=234 in the non-gBRCAmut cohort) or placebo (n=65 in the gBRCAmut cohort, n=116 in the non-gBRCAmut cohort). The mean FOSI score at baseline was similar between the two groups (range between 25·0–25·6 in the two groups). Overall QOL scores remained stable during the treatment and preprogression period in the niraparib group; no significant differences were observed between the niraparib and placebo group, and preprogression EQ-5D-5L scores were similar between the two groups in both cohorts (0·838 [0·0097] in the niraparib group vs 0·834 [0·0173] in the placebo group in the gBRCAmut cohort; and 0·833 [0·0077] in the niraparib group vs 0·815 [0·0122] in the placebo group in the non-gBRCAmut cohort). The most common adverse events reported at screening (baseline) were lack of energy (425 [79%]; 97 [18%] reporting severe lack of energy), pain (236 [44%]), and nausea (118 [22%]). All symptoms, except nausea, either remained stable or improved over time in the niraparib group. The most common grade 3 or 4 toxicities observed in the niraparib group were haematological in nature: thrombocytopenia (124 [34%] of 367 patients), anaemia (93 [25%]), and neutropenia (72 [20%]); disutility analyses showed no significant QOL impairment associated with these toxic effects. Interpretation: These PRO data suggest that women who receive niraparib as maintenance treatment for recurrent ovarian cancer after responding to platinum treatment are able to maintain QOL during their treatment when compared with placebo. Funding: TESARO.
|
|
| 10. |
|
|
| 11. |
- Campbell, Rachel, et al.
(författare)
-
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
- 2022
-
Ingår i: Gynecologic Oncology. - : ACADEMIC PRESS INC ELSEVIER SCIENCE. - 0090-8258 .- 1095-6859. ; 166:2, s. 254-262
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose. The Measure of Ovarian Symptoms and Treatment (MOST) concerns is a validated patient-reported symptom assessment tool for assessing symptom benefit and adverse effects of palliative chemotherapy in women with recurrent ovarian cancer (ROC). We aimed to examine (i) how symptoms within MOST symptom indexes track together (i.e. co-occur) and (ii) the association between MOST symptom indexes and key aspects of health-related quality of life (HRQL). Method. A prospective cohort of women with ROC completed the MOST-T35, EORTC QLQ-C30 and EORTC QLQ-OV28 at baseline and before each cycle of chemotherapy. Analyses were conducted on baseline and end -of-treatment data. Exploratory factor analysis and hierarchical cluster analysis identified groups of co-occurring symptoms. Path models examined associations between MOST symptom indexes and HRQL. Results. Data from 762 women at baseline and 681 at treatment-end who completed all 22 symptom-specific MOST items and at least one HRQL measure were analysed. Four symptom clusters emerged at baseline and treatment-end: abdominal symptoms, symptoms associated with peripheral neuropathy, nausea and vomiting, and psychological symptoms. Psychological symptoms (MOST-Psych) and symptoms due to disease (ovarian cancer) or treatment (MOST-DorT) were associated with poorer scores on QLQ-C30 and OV28 functioning do-mains and worse overall health at both time points. Conclusion. Four MOST symptom clusters were consistent across statistical methods and time points. These findings suggest that routine standardized assessment of psychological and physical symptoms in clinical prac-tice with MOST plus appropriate symptom management referral pathways is an intervention for improving HRQL that warrants further research. (c) 2022 Elsevier Inc. All rights reserved.
|
|
| 12. |
- Flagg, Laura, et al.
(författare)
-
Debris Disks Can Contaminate Mid-infrared Exoplanet Spectra: Evidence for a Circumstellar Debris Disk around Exoplanet Host WASP-39
- 2024
-
Ingår i: Astrophysical Journal Letters. - 2041-8213 .- 2041-8205. ; 969:1
-
Tidskriftsartikel (refereegranskat)abstract
- The signal from a transiting planet can be diluted by astrophysical contamination. In the case of circumstellar debris disks, this contamination could start in the mid-infrared and vary as a function of wavelength, which would then change the observed transmission spectrum for any planet in the system. The MIRI/Low Resolution Spectrometer WASP-39b transmission spectrum shows an unexplained dip starting at ∼10 μm that could be caused by astrophysical contamination. The spectral energy distribution displays excess flux at similar levels to that which are needed to create the dip in the transmission spectrum. In this Letter, we show that this dip is consistent with the presence of a bright circumstellar debris disk, at a distance of >2 au. We discuss how a circumstellar debris disk like that could affect the atmosphere of WASP-39b. We also show that even faint debris disks can be a source of contamination in MIRI exoplanet spectra.
|
|
| 13. |
|
|
| 14. |
- Hoeijmakers, H. J., et al.
(författare)
-
Hot Exoplanet Atmospheres Resolved with Transit Spectroscopy (HEARTS) : IV. A spectral inventory of atoms and molecules in the high-resolution transmission spectrum of WASP-121 b
- 2020
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 641
-
Tidskriftsartikel (refereegranskat)abstract
- Context. WASP-121 b is a hot Jupiter that was recently found to possess rich emission (day side) and transmission (limb) spectra, suggestive of the presence of a multitude of chemical species in the atmosphere. Aims. We survey the transmission spectrum of WASP-121 b for line-absorption by metals and molecules at high spectral resolution and elaborate on existing interpretations of the optical transmission spectrum observed with the Hubble Space Telescope (HST). Methods. We applied the cross-correlation technique and direct differential spectroscopy to search for sodium and other neutral and ionised atoms, TiO, VO, and SH in high-resolution transit spectra obtained with the HARPS spectrograph. We injected models assuming chemical and hydrostatic equilibrium with a varying temperature and composition to enable model comparison, and employed two bootstrap methods to test the robustness of our detections. Results. We detect neutral Mg, Na, Ca, Cr, Fe, Ni, and V, which we predict exists in equilibrium with a significant quantity of VO, supporting earlier observations by HST/WFC3. Non-detections of Ti and TiO support the hypothesis that Ti is depleted via a cold-trap mechanism, as has been proposed in the literature. Atomic line depths are under-predicted by hydrostatic models by a factor of 1.5 to 8, confirming recent findings that the atmosphere is extended. We predict the existence of significant concentrations of gas-phase TiO2, VO2, and TiS, which could be important absorbers at optical and near-IR wavelengths in hot Jupiter atmospheres. However, accurate line-list data are not currently available for them. We find no evidence for absorption by SH and find that inflated atomic lines can plausibly explain the slope of the transmission spectrum observed in the near-ultraviolet with HST. The Na I D lines are significantly broadened (FWHM ∼50 to 70 km s-1) and show a difference in their respective depths of ~15 scale heights, which is not expected from isothermal hydrostatic theory. If this asymmetry is of astrophysical origin, it may indicate that Na I forms an optically thin envelope, reminiscent of the Na I cloud surrounding Jupiter, or that it is hydrodynamically outflowing.
|
|
| 15. |
|
|
| 16. |
- Leblanc, F., et al.
(författare)
-
Ganymede's atmosphere as constrained by HST/STIS observations
- 2023
-
Ingår i: Icarus. - : Elsevier BV. - 0019-1035 .- 1090-2643. ; 399
-
Tidskriftsartikel (refereegranskat)abstract
- A new analysis of aurora observations of Ganymede's atmosphere on the orbital leading and trailing hemispheres has been recently published by Roth et al. (2021), suggesting that water is its main constituent near noon. Here, we present two additional aurora observations of Ganymede's sub-Jovian and anti-Jovian hemispheres, which suggest a modulation of the atmospheric H2O/O-2 ratio on the moon's orbital period, and analyze the orbital evolution of the atmosphere. For this, we propose a reconstruction of aurora observations based on a physical modelling of the exosphere taking into account its orbital variability (the Exospheric Global Model; Leblanc et al., 2017). The solution described in this paper agrees with Roth et al. (2021) that Ganymede's exosphere should be dominantly composed of water molecules. From Ganymede's position when its leading hemisphere is illuminated to when it is its trailing hemisphere, the column density of O-2 may vary between 4.3 x 10(14) and 3.6 x 10(14) cm(-2) whereas the H2O column density should vary between 5.6 x 10(14) and 1.3 x 10(15) cm(-2). The water content of Ganymede's atmosphere is essentially constrained by its sublimation rate whereas the O-2 component of Ganymede's atmosphere is controlled by the radiolytic yield. The other species, products of the water molecules, vary in a more complex way depending on their sources, either as ejecta from the surface and/or as product of the dissociation of the other atmospheric constituents. Electron impact on H2O and H-2 molecules is shown to likely produce H Lyman-alpha emissions close to Ganymede, in addition to the observed extended Lyman-alpha corona from H resonant scattering. All these conclusions being highly dependent on our capability to accurately model the origins of the observed Ganymede auroral emissions, modelling these emissions remains poorly constrained without an accurate knowledge of the Jovian magnetospheric and Ganymede ionospheric electron populations.
|
|
| 17. |
- Lee, Yeh Chen, et al.
(författare)
-
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer : the Gynecologic Cancer InterGroup-Symptom Benefit Study
- 2022
-
Ingår i: International Journal of Gynecological Cancer. - : BMJ Publishing Group. - 1048-891X .- 1525-1438. ; 32:6, s. 761-768
-
Tidskriftsartikel (refereegranskat)abstract
- Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive with >= 3 lines of chemotherapy (PPS-ROC >= 3). Methods Participants completed the Measure of Ovarian Cancer Symptoms and Treatment (MOST) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 questionnaires at baseline and every 3-4 weeks until progression. Participants were classified symptomatic if they rated >= 4 of 10 in at least one-third of symptoms in the MOST index. Improvement in MOST was defined as two consecutive scores of <= 3 in at least half of the symptomatic items at baseline. Improvement in HRQL was defined as two consecutive scores >= 10 points above baseline in the QLQ-C30 summary score scale (range 0-100). Results Of 948 participants enrolled, 910 (96%) completed baseline questionnaires: 546 with PRR-ROC and 364 with PPS-ROC >= 3. The proportions of participants symptomatic at baseline as per MOST indexes were: abdominal 54%, psychological 53%, and disease- or treatment-related 35%. Improvement was reported in MOST indexes: abdominal 40%, psychological 35%, and disease- or treatment-related 38%. Median time to improvement in abdominal symptoms occurred earlier for PRR-ROC than for PPS-ROC >= 3 (4 vs 6 weeks, p=0.044); median duration of improvement was also similar (9.0 vs 11.7 weeks, p=0.65). Progression-free survival was longer among those with improvement in abdominal symptoms than in those without (median 7.2 vs 2.5 months, p<0.0001). Improvements in HRQL were reported by 77/448 (17%) with PRR-ROC and 61/301 (20%) with PPS-ROC >= 3 (p=0.29), and 102/481 (21%) of those with abdominal symptoms at baseline. Conclusion Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants.
|
|
| 18. |
- Mirza, Mansoor Raza, et al.
(författare)
-
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
- 2022
-
Ingår i: Cancer Research Communications. - : AMER ASSOC CANCER RESEARCH. - 2767-9764. ; 2:11, s. 1436-1444
-
Tidskriftsartikel (refereegranskat)abstract
- In this analysis, we examined the relationship between progression-free survival (PFS) and mutation status of 18 homologous recombination repair (HRR) genes in patients in the non-germline BRCA-mutated (non-gBRCAm) cohort of the ENGOT-OV16/NOVA trial (NCT01847274), which evaluated niraparib maintenance therapy for patients with recurrent ovarian cancer. This post hoc exploratory biomarker analysis was performed using tumor samples collected from 331 patients enrolled in the phase III ENGOT-OV16/NOVA trial's non-gBRCAm cohort. Niraparib demonstrated PFS benefit in patients with either somatic BRCA-mutated (sBRCAm; HR, 0.27; 95% confidence interval, CI, 0.08–0.88) or BRCA wild-type (BRCAwt; HR, 0.47; 95% CI, 0.34–0.64) tumors. Patients with BRCAwt tumors with other non-BRCA HRR mutations also derived benefit from niraparib (HR, 0.31; 95% CI, 0.13–0.77), as did patients with BRCAwt/HRRwt (HRR wild-type) tumors (HR, 0.49; 95% CI, 0.35–0.70). When patients with BRCAwt/HRRwt tumors were further categorized by genomic instability score (GIS), clinical benefit was observed in patients with homologous recombination–deficient (GIS ≥ 42; HR, 0.33; 95% CI, 0.18–0.61) and in patients with homologous recombination–proficient (HRp; GIS < 42; HR, 0.60; 95% CI, 0.36–0.99) disease. Although patients with sBRCAm, other non-BRCA HRR mutations, or GIS ≥ 42 benefited the most from niraparib treatment, PFS benefit was also seen in HRp (GIS < 42) patients without HRR mutations. These results support the use of niraparib in patients with recurrent ovarian cancer regardless of BRCA/HRR mutation status or myChoice CDx GIS.Significance:We retrospectively evaluated the mutational profile of HRR genes in tumor samples from 331 patients from the non-germline BRCA-mutated cohort of the phase III NOVA trial of patients with platinum-sensitive high-grade serous ovarian cancer. Patients with non-BRCA HRR mutations generally benefited from second-line maintenance treatment with niraparib compared with placebo.
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
- Roth, Lorenz, et al.
(författare)
-
Ganymede’s tenuous atmosphere
- 2024. - 1
-
Ingår i: Ganymede. - Cambridge, UK : Cambridge University Press.
-
Bokkapitel (refereegranskat)abstract
- Ganymede possesses a tenuous water-based atmosphere, thought to be produced by the solar and Jovian plasma irradiation of its icy surface. Observational evidence for Ganymede's atmosphere is provided by far-ultraviolet (FUV) emission from the atomic oxygen (O) and hydrogen (H) constituents. The relative strengths of the two observed FUV atomic oxygen emission multiplets, which are produced by electron-impact on the atmosphere, allow inference of molecular O2 and H2O components and their relative abundances. Minor species besides O and H have not been detected and the observational constraints can be considered loose overall, partly due to the inherent ambiguity and difficulty in relating the electron-excited emissions to atmospheric properties. Much of our understanding of the configuration of Ganymede’s atmosphere is based on modelling efforts. The modelling studies suggest that O2 is produced primarily through radiolysis and sputtering by the plasma precipitation in the icy polar regions. Since it does not condense, O2 is yet abundant everywhere and likely the dominant species over most of the surface. Ice sublimation increases the abundance of H2O near the sub-solar point, locally exceeding the O2 abundance. The high altitudes, in contrast, are expected to be primarily populated by the lighter H2 molecules everywhere. Inferred column densities for the primary molecules, O2 and H2O, are on the order of 1014 cm-2 to 1015 cm-2. In addition, models suggest that the atmosphere is collisional only up to a few tens of kilometers above the surface, particular in the dense sub-solar region.
|
|
